With over 20 years of experience in the real estate and branded residence sector, Catherine Chan is the Chief Development Officer at Hotel101 Global, a worldwide hotel operator and subsidiary of DoubleDragon Corporation. In this role, she leverages her expertise in new business development, market research, and strategy to drive global sales expansion and project development through franchises and partnerships.
Prior to joining Hotel101 Global, Catherine held several senior positions at Accor, the world’s leading hospitality group. She was the VP, Accor One Living and Global Brand Advisory Lead, heading up Accor’s mixed-use business and solidifying its leadership position as the #2 operator of branded residences worldwide. She also served as the Global Director of Residential Marketing, where she created and executed marketing strategies for Accor’s residential portfolio across 25 countries. Catherine has a proven track record of delivering results and value for her clients, partners, and stakeholders in the highly competitive and dynamic real estate industry.
With over 26 years of diverse technology experience spanning retail real estate, finance, and FMCG sectors, I am poised to bring about sustainable change and establish new industry best practices in my next career endeavor. My aspiration is to lead and mentor cross-functional teams, equipping them to seize fresh business opportunities and tackle emerging challenges, ultimately steering the business towards a transformative paradigm shift.
Digital Transformational Leadership:
My experience includes leadership roles in complex matrix organizations, where I guide corporate and business teams towards innovative directions that reshape fundamental business processes and models. This involves articulating a clear vision, defining strategic goals, and driving actionable steps leading to tangible deliverables. I thrive as a dynamic self-starter, motivating teams to align with the core vision while acquiring new competencies. Notable achievements include spearheading comprehensive digital transformations spanning various areas, from leasing and loyalty to digital workplace solutions, infrastructure, data analytics, and process automation.
Technology Innovation and Business Integration:
In an ever-evolving and disruptive technology landscape, I have empowered my teams to stay agile in response to market dynamics while maintaining a balance with enterprise-level scalability and modular system architecture. Collaborating with key executives across diverse business functions, I’ve ensured that technology solutions align with business needs and are operationally deployable. This approach accelerates time-to-market, centers on user-centricity, and delivers tangible business returns. My expertise lies in bridging the gap between innovation and its effective integration into the core business fabric.
Ms. Jihong He, joined H World Group in October 2021. Prior to joining the Company, Ms. He was the Chief Corporate Strategy Officer and CEO of the Data Center of CapitaLand (SGX: C31) from July 2019 to August 2021. Prior to that, she worked with Temasek, including serving as a director and a managing director, successively, of Temasek International from July 2013 to March 2018, and as the chief strategy officer and chief investment officer of Ascendas-Singbridge, a Temasek portfolio company, from June 2015 and June 2019. Prior to that, she worked for Roland Berger Strategy Consultants (“Roland Berger”), with the latest position as a principal and a member of the Asia Leadership Team. Before joining Roland Berger, Ms. He worked as a senior manager in global investments & terminal operations at Fraport AG from January 2002 to August 2005. She started her career as a product manager of the global marketing chemicals division at BASF SE in Germany in 1997. Ms. He obtained her MBA degree from the University of British Columbia in Canada.
Anmol is currently the Head of Development, Asia Pacific & Middle East for Generator – voted one of the top 50 Most Innovative Global Companies by Fast Company. Anmol’s appointment follows a record-breaking year for the business and movements to consolidate its presence in key markets across Europe and the United States. Given the growing interest and the success of the unique hybrid accommodation model, Anmol has been tasked with spearheading the expansion of Generator’s business into key destinations across the APAC & Middle East regions under its two hybrid-hotel brands Generator & Freehand Hotels.
Generator and Freehand Hotels are a collection of lifestyle and design-led boutique hotels, offering a broad spectrum of accommodation ranging from shared dormitories to private rooms and luxurious penthouse suites. Complemented by a plethora of award-winning food and beverage outlets, including poolside rooftop bars, eclectic restaurants, and lively clubs, each property delivers unforgettable experiences for guests while concurrently maximizing profitability.
With a significant footprint in the most trending European and North American destinations, Generator and Freehand Hotels are now poised for expansion and currently exploring opportunities in key tourism hubs across the Middle East and Asia Pacific, with a diversified approach that includes real estate acquisitions, leases, and management agreements tailored to individual assets or comprehensive portfolios.
Before joining Generator, Anmol held key Development appointments including leading and implementing development strategies as Vice President of Development, Asia Pacific and Middle East at Standard International’s Bangkok-based office. Anmol also oversaw development initiatives at Singapore-based Park Hotel Group and the global Jumeirah Group’s Asia Business Unit, managing large property portfolios and expansion – covering various segments including Luxury, Lifestyle and Upscale across the regions.
Stefanie Kuhner has 20 years of experience working in Clinical Technology and Patient Recruitment & Engagement. She currently is Global Head of Clinical Technology, Innovation & Patient Recruitment – R&D Strategic Sourcing & Procurement at Bristol-Myers Squibb. Prior to joining BMS, Stefanie worked in Medication Compliance & Adherence building, leading AiCure’s Commercial Organization. She spent 14 years in Patient Recruitment & Engagement with Acurian (AES) before joining the AiCure team and started her career at TransPerfect Translations.
Brian joined, the then WestRock, in 2018 as Vice President Global Adherence & Clinicals – the business unit focused on providing Adherence focused, patient centric and Child Resistant Senior Friendly (CR-SF) packaging & service solutions to the Pharmaceutical, Biotech & Clinical Trial industries.
Having majored in marketing, business studies and finance Brians key expertise has been developing packaging solutions supplied to these key markets. Holding a wide range of increasingly elevated positions within companies such as Cardinal Health, Catalent and across several other packaging entities, Brian has gained invaluable insights and a thorough understanding of the demanding requirements, operating systems and ethos of the various market sectors that Smurfit Westrock support today.
Within the last number of years Brian’s focus, together with his globally based team, has been to strategically develop a bespoke, best in class global supply infrastructure within the Smurfit Westrock specialized field of Adherence, Clinical Trial and SMART digital & electronic platforms. These cutting-edge solutions encompass electronically enhanced SMART measure and monitor packaging solutions, such as Cere®Pak, together with developing the vision and capabilities of Cere®Screen Digital Display Labels within the Clinical Trial Supplies arena..
Bernard Vrijens is Chief Executive Officer at Advanced Analytical Research on Drug Exposure (AARDEX Group). He is also Invited Professor of Biostatistics at Liège University, Belgium.
Dr. Vrijens holds a PhD from the Department of Applied Mathematics and Informatics from Ghent University, Belgium.
Dr Vrijen’s currently leads a research programme investigating (a) the most common errors in dosing using a simple but robust taxonomy, (b) particular dosing errors that can jeopardise the efficacy of a drug, and (c) the optimal measurement-guided medication management programme that can enhance adherence to medications and maintain long-term persistence.
Dr. Vrijens is a co-author of seven book chapters, over 100 peer-reviewed scientific papers, and named as inventor on 6 patents. He is a founding member of the International Society for Patient Adherence (ESPACOMP), and an active member of several EU- and US-funded collaborative projects around the theme of adherence to medications.
Dr. Vrijens is a highly-accomplished public speaker, having presented lectures at over 200 industry events and scientific conferences around the world over the past 20 years. Public speaking experience includes the NIH Adherence Network Distinguished Speaker Webinar Series, CDER Drug Packaging Summit at FDA, European Society of Cardiology Congress, American Society on Pharmacometrics, WHO Global Forum on Innovation for Aging Populations, among many others.
